The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index; none of the 2 sources its claims cite is checked for support yet.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 2 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 2
In the paper
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
What the sources say
- Not checked yetcites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
What the sources say
- Not checked yetcites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
In the citing paper
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
In the citing paper
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citation
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 646
Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H., Aviszus, K., Zelarney, P. T., Liao, S., Gerber, A. N., Make, B. J., Wechsler, M. E., Marrack, P., & Reinhardt, R. L. (2023) · ERJ Open Research · doi:10.1183/23120541.00400-2023 · Cited by 7
Montagud, A. C., Vicente-Alcalde, N., Bravo, E. M. G., Sánchez, J. A. H., Penadés, E. M., Egoavil, C. M., Chavarría-Alarcón, E., Caballero, P., & Tuells, J. (2023) · PubMed Central · Cited by 6
Nair, S., & Chen, X. (2021) · Global Health Journal · doi:10.1016/j.glohj.2021.11.005 · Cited by 6
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Lim, H. Y., Arip, M., Yahaya, A. A. A.-F. B., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5024 · Cited by 6
Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
Chang, A., & Yu, J. (2022) · Viruses · doi:10.3390/v14020380 · Cited by 6
Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm
Abusalah, M. A. H., Khalifa, M., Al-Hatamleh, M. A. I., Jarrar, M., Mohamud, R., & Yean, C. Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030386 · Cited by 6
6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers
Cham, J., Pandey, A. C., New, J., Huynh, T. R., Hong, L. K., Orendain, N., Topol, E. J., & Nicholson, L. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266781 · Cited by 7
Bhiman, J. N., & Moore, P. L. (2022) · Immunological Reviews · doi:10.1111/imr.13086 · Cited by 7
Poh, X. Y., Lee, I. R., Lim, C., Teo, J., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Kline, S., Ng, L. F. P., et al. (2022) · Trials · doi:10.1186/s13063-022-06345-2 · Cited by 6
Lessons from a large-scale COVID-19 vaccine trial
Mahla, R. S., & Dustin, L. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163202 · Cited by 6
Answers to common questions about COVID‐19 vaccines in children with cancer
Caniza, M. A., Homsi, M. R., Bate, J. M., Adrizain, R., Ahmed, T., Alexander, S. W., Bhattacharyya, A., Copado-Gutiérrez, J. L., Gutiérrez-Tobar, I. F., Lim, Y. Y., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29985 · Cited by 6
de Boer, J., Saade, U., Granjon, E., Trouillet‐Assant, S., Saade, C., Pottel, H., Zrein, M. A., & Covid ser study group (2022) · PLoS ONE · doi:10.1371/journal.pone.0274553 · Cited by 6
Petrović, V., Vuković, V., Patić, A., Marković, M., & Ristić, M. (2022) · Vaccines · doi:10.3390/vaccines11010056 · Cited by 6
Abdoli, A., Jamshidi, H., Taqavian, M., Baghal, M. L., & Jalili, H. (2024) · Scientific Reports · doi:10.1038/s41598-023-50822-w · Cited by 7
Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis
Beard, K., & Sriwastava, S. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120034 · Cited by 6
Zhao, Y., Wich, D., & Xu, Q. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00793 · Cited by 6
Karłowicz, K., Lewandowski, K., Tulewicz-Marti, E. M., Maciejewska, K., Tworek, A., Stępień-Wrochna, B., Głuszek–Osuch, M., Łodyga, M., & Rydzewska, G. M. (2023) · Gastroenterology Review · doi:10.5114/pg.2023.130126 · Cited by 5
Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Dai, X., Yang, T., Zhao, D. B., & Wang, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149038 · Cited by 5
Vu, M. N., Neil, J. A., Mackenzie-Kludas, C., Kelly, A., Tan, H., Subbarao, K., Lee, W. S., & Wheatley, A. K. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102873 · Cited by 5
Distinct SARS-CoV-2 populational immune backgrounds tolerate divergent RBD evolutionary preferences
Ma, W., Fu, H., Jian, F., Cao, Y., & Li, M. (2024) · National Science Review · doi:10.1093/nsr/nwae196 · Cited by 5
Patel, N., Bouchard, J. L., Oliver, M. B., Badowski, M. E., Carreno, J. J., & the Society of Infectious Diseases Pharmacists (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2622 · Cited by 5
Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization
Beijnen, E. M. S., Odumade, O. A., & van Haren, S. D. (2023) · Vaccines · doi:10.3390/vaccines11030509 · Cited by 5
Wolszczak-Biedrzycka, B., Bieńkowska, A., Cieślikiewicz, B., Smolińska-Fijołek, E., Biedrzycki, G., & Dorf, J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2182907 · Cited by 7
Competing Heterogeneities in Vaccine Effectiveness Estimation
Nikas, A., Ahmed, H., & Zarnitsyna, V. I. (2023) · Vaccines · doi:10.3390/vaccines11081312 · Cited by 7
Self-citationRole Of Vaccines Against COVID-19 Pandemic
Mahdi, P. D. B. M., & Almukhtar, M. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.07.002 · Cited by 5
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5
Rodríguez‐Espinosa, D., Broseta, J. J., Bedini, J. L., Rodríguez, N., & Maduell, F. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab282 · Cited by 5
Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation
Ma, J., Cheng, Z. J., Xue, M., Huang, H., Li, S., Fang, Y., Zeng, Y., Lin, R., Liang, Z., Liang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.913732 · Cited by 5
Kamal, S. M., Naghib, M. M., Daadour, M., Alsuliman, M. N., Alanazi, Z. A., Basalem, A., Alaskar, A. M., & Saed, K. (2023) · Viruses · doi:10.3390/v15020326 · Cited by 5
Asashima, H., Kim, D., Wang, K., Lele, N., Buitrago-Pocasangre, N., Lutz, R., Cruz, I., Raddassi, K., Ruff, W. E., Racke, M. K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168102 · Cited by 5
Sanna, G., Marongiu, A., Firinu, D., Piras, C., Franci, G., Galdiero, M., Pala, G., Palmas, V., Angius, F., Littera, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10040531 · Cited by 5
Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera
Jacobsen, H., Sitaras, I., Jurgensmeyer, M., Mulders, M. N., Goldblatt, D., Feikin, D. R., Bar‐Zeev, N., Higdon, M. M., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10060850 · Cited by 5
What to Expect from COVID-19 and from COVID-19 Vaccine for Expecting or Lactating Women
Gangi, R., Corrias, A., Pintus, R., Marcialis, M. A., & Fanos, V. (2022) · Pediatric Reports · doi:10.3390/pediatric14020034 · Cited by 5
Fernández‐Rivas, G., Barallat, J., Quirant‐Sánchez, B., González, V., Doladé, M., Martínez-Cáceres, E. M., Piña, M., Matlló, J., Blanco, I., & Cardona, P.-J. (2022) · Viruses · doi:10.3390/v14071385 · Cited by 5
Hong, H., Noh, J. Y., Lee, H., Choi, S., Choi, B., Kim, J. K., & Shin, E. (2022) · Immune Network · doi:10.4110/in.2022.22.e23 · Cited by 5
Tuaillon, É., Pisoni, A., Veyrenche, N., Rafasse, S., Niel, C., Gros, N., Muriaux, D. M., Picot, M., Aouinti, S., de Perre, P. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18041-x · Cited by 5
Toya, T., Atsuta, Y., Sanada, T., Honda, T., Sadato, D., Sekiya, N., Kogure, H., Takakuwa, S., Onai, D., Shingai, N., et al. (2022) · Cancer Science · doi:10.1111/cas.15603 · Cited by 5
Barrios, Y., Álava‐Cruz, C., Miranda, D. M., & Matheu, V. M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250509 · Cited by 5
Lozano‐Rodríguez, R., Ortiz, J. A., Terrón, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Mata-Martínez, P., Martín‐Quirós, A., García-Garrido, M. Á., del Balzo‐Castillo, Á., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1136029 · Cited by 6
Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 VariantsPreprint
Luo, G., Hu, Z., & Letterio, J. J. (2021) · medRxiv · doi:10.1101/2021.05.04.21256537 · Cited by 5
A New Saliva-Based Lateral-Flow SARS-CoV-2 IgG Antibody Test for mRNA VaccinationPreprint
Shan, D., Hsiung, J., Bliden, K. P., Zhao, S., Liao, T., Wang, G., Tan, S., Liu, T., Sreedhar, D., Kost, J., et al. (2021) · medRxiv · doi:10.1101/2021.06.11.21258769 · Cited by 5
SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?
Krueger, K., Halasa, N., & Ison, M. G. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.10.003 · Cited by 5
DNA-based vaccines: Advances, applications, and future prospects
Zhou, Z. P., Chen, Z. R., Bandara, R. A., Duan, R. C., Cao, H., Liu, J., & Hu, J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102025 · Cited by 7
Pavlidis, G., Giannoulis, V., Pirounaki, M., Lampropoulos, I. C., Siafi, E. P., Nitsa, A., Pavlou, E. G., Xanthaki, A., Perlepe, G., Fortis, S. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060910 · Cited by 4
Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis
Hergenroeder, G. E., Faino, A., Cogen, J. D., Genatossio, A., McNamara, S., Pascual, M., & Hernandez, R. E. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26528 · Cited by 4
Schmiedeberg, K., Abela, I. A., Pikor, N. B., Vuilleumier, N., Schwarzmüller, M., Epp, S., Pagano, S., Grabherr, S., Patterson, A. B., Nussberger, M., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002575 · Cited by 5
Yeo, J. G., Teh, K. L., Chia, W. N., Book, Y. X., Hoh, S. F., Gao, X., Das, L., Zhang, J., Sutamam, N. B., Poh, S. L., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead031 · Cited by 4
Anti-Spike Antibodies Present in the Milk of SARS-CoV-2 Vaccinated Mothers Are Complement-Activating
Agostinis, C., Toffoli, M., Balduit, A., Mangogna, A., Yasmin, H., Ragazzon, C., Pegoraro, S., Campisciano, G., Stabile, G., Zito, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054395 · Cited by 4
Li, D., Zhao, H., Liao, Y., Jiang, G., Cui, P., Zhang, Y., Yu, L., Fan, S., Li, H., & Li, Q. (2023) · Vaccines · doi:10.3390/vaccines11050963 · Cited by 4
Piñana, J. L., Guerreiro, M., & Solano, C. (2023) · Hemato · doi:10.3390/hemato4020014 · Cited by 4
Younes, S. N., Nicolai, E., Al‐Sadeq, D. W., Younes, N., Al-Dewik, N. I. E., Abou-Saleh, H., Halawa, B. Y. A., Eid, A. H., Pieri, M., Liu, N., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.009 · Cited by 4
Ahmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4
Management of vaccinations in patients with non‐Hodgkin lymphoma
Merli, M., Costantini, A., Tafuri, S., Bavaro, D. F., Minoia, C., Meli, E., Luminari, S., & Gini, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19422 · Cited by 5
Barrios, Y., Álava‐Cruz, C., Franco, A., & Matheu, V. M. (2022) · Diagnostics · doi:10.3390/diagnostics12061421 · Cited by 4
Coronavirus disease 2019 and the cardiologist
Mohammad, K. O., Rodriguez, J. B. C., & Urey, M. A. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000958 · Cited by 4
Choi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Lee, Y. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11010120 · Cited by 4
Stampfer, S. D., Bujarski, S. E., Goldwater, M., Jew, S. K., Regidor, B. S. S., Chen, H., Xu, N., Li, M., Fung, E., Swift, R. A., et al. (2023) · Cancer Reports · doi:10.1002/cnr2.1803 · Cited by 5
Barrufet, M., Serra‐Prat, M., Palomera, E., Ruiz, A., Tapias, G., Montserrat, N., Valladares, N., Ruz, F. J., Bolívar-Prados, M., & Clavé, P. (2023) · European Journal of Public Health · doi:10.1093/eurpub/ckad093 · Cited by 4
Basto-Abreu, A. C., Carnalla, M., Torres‐Ibarra, L., Sánchez‐Pájaro, A., Martínez, M. R., Martínez-Barnetche, J., López-Martı́nez, I., Aparicio‐Antonio, R., Shamah‐Levy, T., Alpuche-Aranda, C. M., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29038 · Cited by 4
SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy
Lu, L., Chan, C., Lim, Y. Y., Than, M., Teo, S., Lau, P. Y.-W., Ng, K. H., & Yap, H. (2023) · Vaccines · doi:10.3390/vaccines11121864 · Cited by 4
BNT162b2 mRNA COVID-19 Vaccine Elicited Antibody Responses in COVID-19-naive Subjects
Lau, C. S., Phua, S. K., Liang, Y. L., Lin, M., & Aw, T. C. (2021) · Journal of Experimental Pathology · doi:10.33696/pathology.2.023 · Cited by 4
Shinde, V., Koen, A. L., Hoosain, Z., Archary, M., Bhorat, Q. E., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2425147 · Cited by 3
Hickey, T. E., Mudunuri, U. S., Hempel, H., Kemp, T. J., Roche, N., Talsania, K., Sellers, B. A., Cherry, J. M., & Pinto, L. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1502458 · Cited by 3
Patel, R. S., & Agrawal, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619882 · Cited by 3
Styles, T. M., Akhtar, A., Gu, C., Neumann, G., Muramatsu, H., McPartlan, J. S., Talukder, P., Gratz, D., Stokdyk, K., Turner, H. L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102369 · Cited by 3
COVID-19 and isolation: Risks and implications in the scenario of new variants
Dias, V. M. D. C. H., Oliveira, A. F., Marinho, A. K. B. B., Ferreira, C. E. D. S., Domingues, C. E. F., Fortaleza, C. M. C. B., Vidal, C. F. D. L., Carrilho, C. M. D. D. M., Pinheiro, D. O. B. P., de Assis, D. B., et al. (2022) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2022.102703 · Cited by 3
Klingel, H., Krüttgen, A., Imöhl, M., & Kleines, M. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.60 · Cited by 3
Shen, C., Fu, Y.-C., Ho, T., Chen, P., Lee, N., Tsai, B., Tsai, P.-J., Ko, W., Liu, H., Cheng, C., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109342 · Cited by 3
Hussein, M., Mumtaz, M., Nasir, I., & Abdullahi, A. (2023) · Biology Medicine & Natural Product Chemistry · doi:10.14421/biomedich.2023.121.343-361 · Cited by 3
Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination
Montmaneix-Engels, F., Dimeglio, C., Staes, L., Silva, I. D., Porcheron, M., Jougla, I., Hérin, F., & Izopet, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29116 · Cited by 4
Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network
Atmar, R. L., Abate, G., Deming, M. E., George, S. L., Fleming, A. B., Frey, S. E., Lyke, K. E., Stephens, D. S., del Río, C., & Sahly, H. M. E. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf380 · Cited by 3
Windpessl, M., Heine, G. H., Becker, S. L., Scheuer, A. L., Sester, M., & Kronbichler, A. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1550-7288 · Cited by 3
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
Marković, M. (2021) · Medicinski podmladak · doi:10.5937/mp72-33315 · Cited by 3
Application of SARS-CoV-2 Serology to Address Public Health Priorities
Sherman, A. C., Smith, T., Zhu, Y., Taibl, K. R., Howard-Anderson, J. R., Landay, T., Pisanic, N., Kleinhenz, J., Simon, T. W., Espinoza, D., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.744535 · Cited by 3
Self-citationOmae, Y., Sasaki, M., Toyotani, J., Hara, K., & Takahashi, H. (2022) · IEEE Access · doi:10.1109/access.2022.3168985 · Cited by 3
Irsan, A., Mardhia, M., & Rialita, A. (2022) · Muhammadiyah Medical Journal · doi:10.24853/mmj.3.1.27-32 · Cited by 3
Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
Lu, B., Zhu, K.-L., Cui, X.-M., Lin, Y., Wang, X., Wang, G., Duan, L., Qian, A., & Ma, M. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109103 · Cited by 3
Tian, Y., Zhang, X., Mu, S., Guo, Y., Xu, X., Huo, J., Wei, Z., Liu, L., Li, X., Li, H., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2141711 · Cited by 3
Antibodies as drugs—a Keystone Symposia report
Cable, J., Saphire, E. O., Hayday, A., Wiltshire, T. D., Mousa, J. J., Humphreys, D. P., Breij, E. C. W., Bruhns, P., Broketa, M., Furuya, G., et al. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14915 · Cited by 3
Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3
Koller, Á., & Szebeni, J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2188035 · Cited by 3
Wolz, O., Vahrenhorst, D., Quintini, G., Lemberg, C., Koch, S. D., Kays, S.-K., Walz, L., Kulkarni, N., Fehlings, M., Wengenmayer, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12040388 · Cited by 3
Serrano‐Conde, E., Leyva, A., Fuentes, A. P., de Salazar, A., Chueca, N., Pérez‐Castro, S., Regueiro, B. J., Rojas, A., Mendoza, J., Rojas, J., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14417 · Cited by 3
Mattila, J., Amaro, A., Longo, M., Antaki, J. F., Koirala, S., & Gandini, A. (2022) · Biomicrofluidics · doi:10.1063/5.0079054 · Cited by 3
Health Certificate Exchange for Travel Management in Pandemic: Review and Perspectives
Shen, B., Tan, W., Cai, H., Jiang, L., Guo, J., & Qin, P. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3202130 · Cited by 3
Dulipsingh, L., Lang, M., Diffenderfer, M. R., Cook, L., Puff, J., Diaz, L., He, L., & Schaefer, E. J. (2022) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2022.100130 · Cited by 3
Belda, F., Mora, O., Christie, R., & Crowley, M. (2022) · Plasmatology · doi:10.1177/26348535221129232 · Cited by 3
Luo, R., Herrera-Reyes, A. D., Kim, Y., Rogowski, S., White, D., & Smirnova, A. (2024) · The IMA volumes in mathematics and its applications · doi:10.1007/978-3-031-58516-6_7 · Cited by 3
Actions and attitudes on the immunized patients against SARS-CoV-2
Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/131.2021 · Cited by 3
Declined Antibody Responses to COVID-19 mRNA Vaccine within First Three MonthsPreprint
Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A. P., Maruste, R., Kärner, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3854683 · Cited by 3
Favresse, J., & Douxfils, J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.001 · Cited by 3
Fernandes, G., Devresse, A., Scohy, A., Yombi, J. C., Belkhir, L., Greef, J. D., Meyer, M. D., Mourad, M., Darius, T., Buemi, A., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003963 · Cited by 3
Sarkar, J., & Sarkar, C. (2024) · Preprints.org · doi:10.20944/preprints202402.1366.v1 · Cited by 3
Perlman, S. M., & Denison, M. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00017-7 · Cited by 2
Formulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor
Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Yang, T., Zhao, D. B., & Wang, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107525 · Cited by 2
Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5
Tamming, L. A., Lansdell, C., Zhang, W., Duque, D., Bavananthasivam, J., Frahm, G. E., Pfeifle, A., Raman, S. N. T., Wu, J., Gravel, C., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01382-3 · Cited by 2
Straus, W. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2653369 · Cited by 3
Goyal, M., Jain, M., Patel, N., & Sharma, A. (2022) · Journal of Indian Academy of Oral Medicine and Radiology · doi:10.4103/jiaomr.jiaomr_338_21 · Cited by 2
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
Rodilla, A. M., Tavolacci, S. C., Cagan, J., Shah, T., Mittan, S., Mack, P. C., & Hirsch, F. R. (2023) · Vaccines · doi:10.3390/vaccines11050969 · Cited by 2
Cui, L., Wang, J., Orlando, F., Giacconi, R., Malavolta, M., Bartozzi, B., Galeazzi, R., Giorgini, G., Pesce, L., Cardarelli, F., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03285 · Cited by 2
Metadata
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
